Filament Health

Psychedelic Medicines Naturally Derived

March 2022

Corporate Presentation

Filament Health

A Powerful Platform to provide safe, natural psychedelics to the world

First FDA clinical trials of natural psychedelics including first-ever investigation of psilocin authorized Q4 2021 at UCSF's TrPR Program

Industry-leading **IP portfolio** featuring first patent granted for natural psilocybin extraction; thirty additional applications

In-house **GMP manufacturing** and regulatory expertise; **revenue-generating** licensing and supply agreements

Health Canada Dealer's License at wholly-owned subsidiary Psilo Scientific covering full range of natural psychedelic compounds

Management and Board accomplished in biotech, IP and pharma, plus forty years of **botanical extraction experience**

Drug discovery program unlocking the potential of dozens of psychedelic species and compounds

Mental Health Crisis

Over 130 active clinical trials[1] globally are seeking to demonstrate that psychedelics represent a potentially far healthier, more effective alternative to the US$280B[2] spent on mental health treatment in North America

Depression

264M+

people suffering globally[3]

$4.0B

annual spend on depression treatment globally[6]

Anxiety

275M+

people suffering globally[4]

$4.5B

annual spend on anxiety treatment globally[6]

Addiction

21M+

people suffering globally[5]

$26.4B

global opioid market (2018)[7]

1. PSYCH: The Psychedelics as Medicine Report, Prohibition Partners, September 2020
2. Projections of National Expenditures for Treatment of Mental & Substance Use Disorders" (SAMHSA)
3. WHO - Depression
4. World Economic Forum - This is the world's biggest mental health problem
5. Addiction Centre - Statistics on Addiction in America
6. IQVIA Global Annual Sales Report (IQVIA, 2020)
7. BCC Research: Opioid Drugs - Global Markets to 2023

Plant Medicine is Big Business

$40B

global revenue of botanical and plant-derived drugs[1]

40%

of western-world pharmacy products are derived from plants[2]

42%

of all new drugs from 1981 to 2019 come from natural origins[3]

Taxus brevifolia → **PACLITAXEL**



For example:

Taxol®, the best-selling cancer drug ever created, is an extract from the yew tree[4]

$1.6B

Annual revenue



1. Statista.com - Global botanical and plant-derived drugs market
2. US Forest Service - Medical Botany
3. Journal of Natural Products - Natural Products as Sources of New Drugs
4. National Cancer Institute - Taxol

Natural Advantage - Drug Discovery

Valuable Compounds Available for the First Time

There are over 100 known species of psilocybin mushrooms[2] and over 100 known psychedelic plants[3]—some have been used safely for over 1000 years[1]. Classification as controlled substances in the 1970s means the valuable medicines in these plants remain almost entirely unexplored by modern science.

Natural extraction is the best way to access the untapped drug discovery potential of hundreds of psychedelic species. Both in isolation or in combinations, naturally-extracted compounds provide a vast number of therapeutic candidates and the exciting potential to prove the "entourage effect" which is not possible with synthetics.

Rather than synthesize new molecules, Filament develops the technology necessary for creating pharmaceutical-grade drug candidates of compounds that already have documented safety and efficacy, creating valuable IP and increasing speed to market.

Anadenanthera peregrina
↓
BUFOTENIN



Echinopsis peruviana
↓
MESCALINE

Mushrooms contain much more than just psilocybin and psychedelics are much more that just mushrooms



Acacia simplex
↓
N,N-DMT

1. US National Library of Medicine, National Institutes of Health - Psychedelics
2. International Journal of Medicinal Mushrooms - Species Diversity of the Genus Psilocybe
3. The ethnobotany of psychoactive plant use: a phyiogenetic perspective

First-Ever Psychedelic Botanical Drug Candidates

Filament's first three candidates are standardized purified extracts of *psilocybe Cubensis* fruiting bodies which have successfully attained FDA botanical drug classification, a unique development pathway with significant IP benefits vs isolated natural and synthetic compounds.

Product Code	Description	Preclinical	Phase I	Phase II
PEX010 (25 mg)	Psilocybin (Oral 25 mg)			
PEX010 (1 mg)	Psilocybin (Oral 1 mg)			
PEX020	Psilocin (Oral, dose withheld)			
PEX030	Psilocin (Sublingual, dose withheld)			
AEX010	Standardized ayahuasca formulation (dose withheld)			
AEX020	Standardized monoamine oxidase inhibitor			

1. Further reading: FDA Botanical Drug Guidance

Standardized Psilocin for the First Time

Filament has developed proprietary technology to extract and standardize this notoriously unstable molecule, sparking the first-ever FDA trial to administer psilocin directly

Psilocybe cubensis



PSILOCYBIN
(Inactive)

Dephosphorylation



PSILOCIN
(Active)

Prodrug vs. Active Drug

Both psilocin and psilocybin are found in magic mushrooms. However, psilocybin is not bioactive in humans and must convert in to psilocin before causing hallucinogenic and therapeutic effects.

Bypassing the conversion by directly administering psilocin could mean faster onset time, fewer side effects, and more consistent dosing.

An Unstable Molecule

Stable synthetic psilocin is extremely difficult to manufacture. Psychedelic companies to date have focused on developing alternative synthetically-derived compounds.

Filament Health has developed proprietary technology capable of producing stable, natural psilocin in addition to psilocybin. This allows it to enter botanical drug candidates featuring each compound into FDA-authorized human clinical trials.

Groundbreaking Natural Psychedelic Clinical Development

Tackling the Mental Health Crisis by advancing the field of psychedelic research with multiple clinical "firsts"

	Drug Candidates	Description	Status
Phase 1 Trial	**PEX010, PEX020, PEX030**	First-ever direct administration of psilocin with IP-protected PEX020 (Oral) and PEX030 (Sublingual); measuring therapeutic effects directly against PEX 010 (Oral Psilocybin 25mg)	FDA Authorization Received Q4 2021, first dosing anticipated March 2022
Phase 2 Trial	**PEX010**	Safety and efficacy PEX010 in Major Depressive Disorder while employing a novel control condition to set a new research standard and overcome a major clinical deficiency.[1]	Anticipated FDA Authorization Q2 2022

Demonstrating the safety and efficacy of natural psychedelics for the first time in human clinical trials:

- Led by **Principal Investigator, Dr. Joshua Woolley, MD/Ph.D.**, experienced psychedelics clinician and researcher
- In close partnership with the **Translational Psychedelic Research Program** at the University of California San Francisco

1. Nature Magazine - How ecstasy and psilocybin are shaking up psychiatry

Enabling a Thriving Research Ecosystem

Filament has partnered with leading researchers worldwide to advance psychedelic research and generate revenue. Filament commits to low- or no-cost study drugs for academic researchers and retains safety data for in-house programs

Sponsor	Revenue-generating	Intervention	Indication	Phase	Location	Application	Approval	Start
Cybin Therapeutics	Yes	PEX010 (25mg)	Depression	2	Canada/ Vancouver	Q4 2021	Q1 2022	Q3 2022
ATMA Journey Centers	Yes	PEX010 (25mg)	Therapist Training	1	Canada/Alberta	Q1 2022	Q1 2022	Q2 2022
EntheoTech	Yes	PEX010 (25mg)	Opioid Tapering	2	Canada/ Okanagan	*Q1 2022**	*Q2 2022**	*Q2 2022**
EntheoTech	Yes	PEX010 (25mg)	Chronic Pain/Depression	2	Canada/ Okanagan	*Q3 2022**	*Q4 2022**	*Q4 2022**
University of Toronto	No	PEX010 (1mg)	Depression	2	Canada/ Toronto	Q4 2021	Q4 2021	Q3 2022
(Withheld)	No	PEX010 (25mg)	Coma	2	EU/(Withheld)	*Q1 2022**	*Q2 2022**	*Q3 2022**
(Withheld)	No	PEX010 (25mg)	Depression	2	EU/(Withheld)	*Q2 2022**	*Q3 2022**	*Q4 2022**

**Anticipated Dates*

Natural Advantage - Intellectual Property

Unlike the nearly unlimited number of synthetic forms and methods, there are finite ways to extract and purify naturally occurring psychedelic compounds.

Prohibition has led to a dearth of extraction experts; few people have the experience to create processes that efficiently make extracts. Of what little literature is published, much is incorrect.

Perfected by nature over millions of years, natural psychedelics can be extracted, purified, and are immediately available as powerful medicines without harmful synthetic chemicals or residues.

Psychedelic Botanical Drug Processing Steps

Propagation
Grow botanical psychedelics

Trade Secrets

Extraction
Remove target compounds from biomass

Patent Families 1, 7, & 8
13 Filed
1 Granted

Purification
Remove undesirable elements

Patent Families 2 & 6
4 Filed

Standardization & Stabilization
Precise and stable dosing

Patent Families 3 & 4
4 Filed

Human Delivery
Compositions of matter for different deliverable forms

Patent Family 5
4 Filed

Synthetic vs Natural IP

Patented and patent-pending technologies cover the limited number of desirable extraction and purification methods that exist

Filament IP	Viable Methods[1]	Methods Covered	Viable Methods Covered	Methods Covered
Extraction	**3** **1 granted** + 2 filed	**15** 3 viable + 12 nonviable "moat"	**100%**	**19** (including psilocybin, DMT, etc.)
Purification	**1**	**2** 1 viable + 1 nonviable "moat"	**100%**	**19** (including psilocybin, DMT, etc.)

VS.

Synthetic IP e.g. COMPASS Pathways	Viable Number	Number Covered	Viable Number Covered	Compounds Covered
Polymorphic Forms	>1,000	1	<0.1%	1
Synthesis Methods	>1,000	1	<0.1%	1

"Our patents do not preclude others from creating a range of different solutions for the synthesis and formulation of psilocybin"[2]
COMPASS Pathways

1. Determined through experimentation
2. Navigating Mental Health: COMPASS Pathways' Psilocybin Research Program (Winter 2018)

Intentionally-Crafted Patent Strategy Validated by First Patent Grant

Protecting Hard Work and Innovation

Filament's IP strategy has been carefully designed to protect its core technology as well as shareholder interests. As all of our drug candidates are naturally-occurring, they cannot be patented. Efforts instead are focused on developing and protecting the transformative technology necessary to elevate natural products to pharmaceutical grade. Plants and fungi in their raw form lack precise potency and dosing, caused by crop-to-crop and flush-to-flush variability. Filament's patent covers technology that ensures its extracts are delivered in measured, repeatable doses.

The first public company to be issued a patent for the extraction of natural psilocybin

Filament's recently issued patent (August 3, 2021) covers the extraction and standardization of natural psilocybin and associated psychoactive compounds. This issuance validates Filament's IP strategy and sets the Company in good stead for allowances of pending patents covering additional elements of its proprietary technologies.

Third-Party Expert Validation

> [Filament][1] has developed a robust and aggressive patent estate covering multiple innovative technologies it has developed in the field of fungal psychoactive extraction, purification, stabilization and formulation and delivery.[1]

Lee A. Johnson, Ph.D., Esq. (April 16, 2021)

1. Patents held in Filament's wholly-owned subsidiary

Natural Advantage - Widespread Adoption

Natural psychedelics will be preferred by patients and therapists in future non-pharmaceutical markets

Filament is committed to sourcing raw ingredients harvested sustainably or cultivated in-house

Non-pharmaceutical markets are emerging. Oregon will [prohibit synthetic psilocybin in a regulated but non-medical setting[1] and Canada has amended the SAP to allow potential access to psilocybin and psilocin[2].

Synthetics are only suitable for pharmaceutical products, which may limit their adoption, and are permitted to contain questionable residues and unidentified byproducts.

Solvent	Residue (ppm)	
	Synthetic (Allowable)	Filament (Actual)
Methyl tert-butyl ether	600	Nil
Tetrahydrofuran	720	Nil
Dichloromethane	600	Nil
Methanol	5,000	< 1,000

Naturals will increase adoption due to:

- Consumer preference
- Limited residues and no byproducts
- Lower cost to manufacture
- **Crucially**: Lower cost to administer

1. Oregon Health Authority - Oregon Psilocybin Services Act (Measure 109)
2. Regulations Amending Certain Regulations Relating to Restricted Drugs (Special Access Program): SOR/2021-271

GMP Facility with Health Canada Dealer's License through wholly-owned subsidiary

Certifications enable Psilo Scientific Ltd. to supply in-house human clinical trials and distribute IP and drug candidates to drug developers, researchers, and other licensed parties

3,500 ft^2 GMP-compliant manufacturing, research, and development facility on BCIT campus

Propagation, extraction, production, distribution, and sale of all natural psychedelic compounds

Ongoing propagation and cultivation research program to identify best strains and genetics. 20+ varieties analyzed

Multiple supply and licensing agreements for drug candidates and IP

In-house manufacturing allows for rapid product/IP development and enables timely fulfillment of partner requests. Current production capacity is >2000 high doses of psilocybin per month

Natural Advantage - Management Team

Deep experience in botanical extraction, intellectual property, biotech, pharma, commercialization, and capital markets

Global Experts in Botanical Extraction and Commercialization

- Scaled Mazza Innovation from pre-seed to $26M sale to Sensient Technologies in 2018
- Developed and commercialized patent-protected, botanical extraction technology at commercial-scale 35,000 sq. ft. GMP facility

Ben Lightburn
CEO, Director
Co-Founder
B.Sc (Physics), MBA
Proven entrepreneur and leader specializing in the research, development and commercialization of novel extraction technologies

Lisa Ranken
Chief Operating Officer
P.Eng, M.Eng
Operational and leadership expertise in rapidly growing industries

Ryan Moss
Director or Research & Development
M. Analytical Chemistry
Expert in the field of botanical extraction, purification, standardization

Beatriz Ramos
Quality Director
B.Sc.
Quality management, regulatory compliance, and attaining third-party certification

Jeff Fellows
Head of Regulatory
B.Sc.
30 years of drug development experience leading regulatory development efforts from pre-IND to post-approval

Taran Grey
Director of IP
BA
Extensive patent and trademark portfolio experience in healthcare, technology and other diversified industries

Warren Duncan
CFO
CPA, B.Comm
Experienced in audit, accounting, capital markets, M&A and equity financing

Anna Cordon
Director of Communications
BA
12+ years of experience leading marketing and communications for global organizations.

Board of Directors and Advisors

Greg Mills

Board Chair

Former Managing Director, Head Global Equities, RBC Capital Markets

Chairman, Sundial Growers Inc.

NEO Exchange, Independent Board member

Maureen O'Connell

Audit Committee Chair

Certified Public Accountant

Previously Audit Committee Chair of Sucampo Pharma (NASDAQ: SCMP) until its sale in 2018

Formerly CFO of Scholastic

Board Member of Harte Hanks, Beazer Homes

Chris Wagner

Director

Over 25 years of experience in the life sciences industry, most recently as CEO and Director of both private and public companies

Led Prozac and Zyprexa teams at Eli Lilly

Founder and VP at Aspreva Pharmaceuticals

Jon Conlin

Director

Partner at Fasken

Corporate and commercial lawyer specializing in companies in the technology and health sciences sectors including venture capitalists and start-ups

Tom Kineshanko

Founding Advisor

Founder, executive, and allocator of capital in regulated frontier markets

Founder of first licensed Bitcoin asset manager in Canada and Swiss hedge fund, Protos Asset Mgmt

50+ seed round investments in companies that have gone on to have >$50B cumulative value

Josh Woolley

Principal Investigator, Advisor

BSc Biology & Psychology, Ph.D Neuroscience, M.D.

Associate Professor in the Department of Psychiatry and Behavioural Sciences at UCSF; PI and Director of UCSF's Bonding and Attunement in Neuropsychiatric Disorders Laboratory

Director of the Translational Psychedelic Research (TrPR) Program at UCSF

Filament Foundation

Supporting the ecosystem, scientists, and advocates

Filament Foundation will fund key actors and initiatives to help ensure a thriving global psychedelics ecosystem:

Filament Founders have pledged 10% of their personal shares to Filament Foundation

Foundation Board is majority outside members of the community

Filament Foundation Board of Directors

Karen Mahon

Former Managing Director: Greenpeace Canada and Public Outreach USA

Joel Solomon

Founder, Renewal Funds

Tom Kineshanko

Ben Lightburn

Vacancy

Public Markets and Capitalization

Current Trading Symbols:

NEO:FH

OTCQB:FLHLF

FSE:7QS

Basic Shares Outstanding	~164.7 million	
Dilutive Securities	Stock Options[1] Performance Warrants Warrants	~15.6 million ~2.0 million ~7.3 million
Fully Diluted Shares Outstanding[2]	~189.6 million	

Note: Figures represent approximations as of June 2021. All figures noted are in Canadian dollars

1. Note 1: Outstanding stock options are issued to employees, directors and advisors with varying expiry dates.
2. Fully Diluted Share Capital assumes vesting and subsequent exercise of all dilutive securities outstanding

Disclaimers

NOTICE TO INVESTORS

This presentation (the "Presentation") is being issued by Filament Ventures Corp. (the "Company") for information purposes only confidential and proprietary materials, and may contain certain material information about the Company, including important disclosures and risk factors applicable to the Company and the proposed private placement offering (the "Offering")of securities of the Company (the "Securities") the proposed as further described in this Presentation. The purpose of this Presentation is to provide information regarding the Company, including with respect to the Company's business and operations, the psychedelics industry generally. This Presentation has not been prepared to assist any reader in making a decision whether to invest in the Company and the contents of this Presentation have not been approved or disapproved by any securities commission or regulatory authority in Canada, the United States or any other jurisdiction. In making an investment decision, prospective investors must rely on their own examination of the Company and the terms of the Offering as further detailed in the term sheet accompanying this Presentation (the "Term Sheet"), including the merits and risks involved in purchasing the Securities. Prospective investors should not construe the contents of this presentation as legal, tax, investment or accounting advice by the Company or any of its directors, officers, shareholders, agents, employees or advisors. This Presentation does not take into account the particular investment objectives or financial circumstances of any prospective investor. Each prospective investor who reviews this Presentation must make its own independent assessment of the Company and the Securities after making such investigations and each prospective investor is strongly urged to consult withits own advisors with respect to legal, tax, regulatory, financial and accounting consequences, including the merits and risks involved, of any investment in the Company and it's Securities.

This Presentation is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of or to make any investments in, the Company in any jurisdiction. Any transaction will not be registered under any securities laws. No securities commission has approved or disapproved or will approve or disapprove of any securities or passed upon the accuracy or adequacy of any information or the merits of any transaction. Any presentation to the contrary may be a criminal offense. No sales will be made, no commitments to invest in the Company will be accepted, and no money is being solicited or will be accepted in connection with this document. Any indication of interest from prospective investors in response to this presentation involves no obligation or commitment of any kind. Any securities will only be sold pursuant to a Definitive Agreement that shall set forth the terms and conditions of the sale of securities.

By purchasing securities offered under this Presentation, each investor is deemed to acknowledge that its express wish is that all documents evidencing or relating in any way to the sale of the Securities be drafted in the English language only. En souscrivant des valeurs mobilières en vertu de la présente notice d'offre, chaque souscripteur est réputé reconnaître avoir exigé que tous les documents faisant foi de ou relatifs à la vente des valeurs mobilières soient rédigés uniquement en anglais.

This Presentation contains highly confidential information regarding the investments, strategy and organization of the Company and is being delivered to you in reliance on your agreement in the following sentences. Your acceptance of this document constitutes, and shall be deemed to constitute, your agreement to (i) keep confidential all the information contained in this Presentation, as well as any information derived by you from the information contained in this Presentation (collectively, "Confidential Information") and not disclose any such Confidential Information to any other person, (ii) not use any of the Confidential Information for any purpose other than to evaluate the purchase of Securities of the Company, (iii) not copy this document without the Company's prior consent, and (iv) promptly return this document and any copies hereof to the Company upon the Company's request.

In making an investment decision, prospective investors should rely on their own examination of the Company and the terms of the Private Placement, including the merits and risks involved. Prospective investors should not construe the contents of this Presentation as legal, tax, investment or accounting advice by the Company or any of its directors, officers, shareholders, agents, employees or advisors. This Presentation does not take into account the particular investment objectives or financial circumstances of any specific party who may receive it. Each party who reviews this Presentation must make its own independent assessment of the Company after making such investigations and each prospective investor is strongly urged to consult with its own advisors with respect to legal, tax, regulatory, financial and accounting consequences, including the merits and the risks involved, of any investment in the Company. In particular, any estimates, projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumption and each recipient should satisfy itself in relation to such matters. Investment in the Company is suitable only for sophisticated investors and requires the financial ability and willingness to accept the high risks and lack of liquidity that are characteristic of an investment in "seed" or "risk" capital for an entity which is in a speculative stage of development.

Certain information contained herein includes market and industry data that has been obtained from or is based upon estimates derived from third party sources, including industry publications, reports and websites. Third party sources may state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance or guarantee as to the accuracy or completeness of included data. Although the data is believed to be reliable, neither the Company nor its agents have independently verified the accuracy, currency, reliability or completeness of any of the information from third party sources referred to in this Presentation or ascertained from the underlying economic assumptions relied upon by such sources. The Company and its agents hereby disclaim any responsibility or liability whatsoever in respect of any third party sources of market and industry data or information.

This Presentation has not been independently verified and the information contained within may be subject to updating, revision, verification and further amendment. Except as otherwise provided for herein, neither the Company, nor its directors, officers, shareholders, agents, employees or advisors give, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, currency, reliability or completeness of the information or opinions in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers and liability therefore is expressly disclaimed for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

Except as may be required by applicable law, in furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies or omissions.

CONFIDENTIALITY NOTICE

Information contained in this Presentation is the property of the Company and it is made available strictly for the purposes referred to above in the "Notice to Investors" (the "Permitted Purpose"). By accepting this Presentation, each recipient agrees that it will not copy, reproduce, disclose or distribute to others this Presentation or the information contained herein, in whole or in part, at any time, without the prior written consent of the Company. The recipient further agrees that it and each of its directors, officers, employees and representatives shall use this Presentation only for the Permitted Purpose and for no other purpose. The recipient acknowledges and agrees that the information contained herein: constitutes the Company's proprietary information; is valuable proprietary and confidential information of the Company developed at considerable cost and effort; and that such information is the sole and exclusive property of the Company. The recipient further acknowledges and agrees that it shall not obtain any rights or licenses in, ownership of or entitlements to any of such proprietary information or any underlying intellectual property rights.

NOTICE REGARDING FORWARD LOOKING INFORMATION

Certain information included in this Presentation constitutes forward looking information under applicable securities legislation that involve substantial known and unknown risks and uncertainties. This information relates to future events or future performance of the Company. Forward-looking information are statements that are not historical facts and are often, but not always, identified using words or phrases such as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "predict", "seek", "propose", "expect", "potential", "continue", and other similar expressions. In particular, but without limiting the foregoing, this Presentation contains forward-looking information pertaining to, among other things: the termsof the transactions involving Psilo and certain other transactions described in this Presentation (the "Transactions"); expectations regarding the timing of steps to complete the Transactions; future growth plans; the capitalization and debt levels of the Company; the intention of the Company to seek out and target acquisitions; the effects of the Transactions; the Company's growth and business strategies; and targeted customer base and resulting revenues in the near to mid term.

By its nature, forward-looking information involves known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated. Such forward-looking information is provided for the purpose of providing information about management's current expectations and plans relating to the future. Investors are cautioned that reliance on such information may not be appropriate for other purposes, such as making investment decisions. These factors and risks include, without limitation: risks that all necessary regulatory and third party approvals will not be forthcoming; risks that parties to the Transactions will not be satisfied with their respective due diligence procedures; risks that the parties will not be able to identify appropriate risks associated with drug development involving extracts from naturally occurring psychedelic alkaloids; exchange rate fluctuations; changes in legislation affecting psilocybin and other psychoactive based compounds and additives; and uncertainties resulting from potential delays or changes in plans with respect to the acquisition and development of future facilities.

With respect to forward looking information in this Presentation, the Company has made assumptions, regarding, among other things: shareholder and regulatory approvals for the Transactions and the receipt of those approvals; assumptions regarding the success of extraction and isolation of natural psychedelic compounds; the expected market size of the global psychedelics industry; the availability of capital; current legislation; and general economic conditions.

Although the Company believes that the expectations reflected in such forward looking information are reasonable, such statements are not guarantees of future performance and actual results may differ materially from those in statements of forward-looking information. Undue reliance should not be placed on forward looking information because the Company can give no assurance that such expectations will prove to be correct and such statements are based on the beliefs, estimates and opinions of the Company's management on the date such statements are made. Many factors could cause the Company's actual results, performance or achievements to vary from those described herein. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward looking information prove incorrect, actual results may differ materially from those described in this Presentation as intended, planned, anticipated, believed, estimated or expected.

The forward-looking information included in this Presentation is expressly qualified in its entirety by this cautionary statement. The Company cautions that the foregoing lists of assumptions, risks and uncertainties is not exhaustive. The forward-looking information contained in this Presentation is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws.

Any financial outlook or future oriented financial information in this document, as defined by applicable securities legislation, has been approved by management of the Company. Such financial outlook or future oriented financial information is provided for the purpose of providing information about management's current expectations and management's plans relating to the future of the Company. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

Market data and industry forecasts contained in this Presentation have been obtained from industry publications, various publicly available sources and subscription-based reports as well as from management's good faith estimates, which are derived from management's knowledge of the industry and independent sources that management believes to be reliable. Industry publications, publicly-available sources and subscription-based reports generally state that the information contained therein has been obtained from sources believed to be reliable. We have not independently verified any of the information from such third-party sources nor have we ascertained the validity or accuracy of the underlying economicassumptions relied upon therein. The Company hereby disclaims any responsibility or liability whatsoever in respect of any third party sources of market and industry data or information.

Filament Health

Contact Us

www.filament.health
#210-4475 Wayburne Drive
Burnaby, BC V5G 4X4

Communications
anna@filament.health

Investor Relations
ir@filament.health

Join Our Mailing List
hello@filament.health